Although most of the patients with
Hodgkin's lymphoma (HL) can be cured by the current regimen of high-dose multiagent
chemotherapy, the treatment causes high risks of later toxicities including secondary
malignancies. Therefore, new rational strategies are needed for HL treatment.
Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a promising
anticancer agent due to its
tumor selectivity and its lack of toxicity for normal cells. Unfortunately, many
cancers remain resistant to TRAIL including HL. HL is characterized by enhanced expression of cellular
caspase-8 (
FLICE)-inhibitory protein (c-FLIP) and X-linked inhibitor of apoptosis (XIAP), which block receptor-mediated apoptosis by inhibiting
caspase-8 and
caspase-3, respectively. We have recently discovered the herbal compound
Rocaglamide, which breaks TRAIL-resistance in
acute T cell leukemia through inhibition of c-FLIP expression. We have also shown that small molecule XIAP inhibitors can sensitize TRAIL-mediated apoptosis in several resistant
tumors. However, whether targeting XIAP or c-FLIP is also a suitable strategy to prime HL cells for TRAIL-induced apoptosis has not yet been investigated. In our study, we show that
Rocaglamide suppresses c-FLIP expression in HL cells in a dose- and time-dependent manner. However, downregulation of c-FLIP alone was not sufficient to sensitize TRAIL-induced apoptosis in HL cells. Similarly, treatment of HL cells with a small molecule XIAP inhibitor resulted in a moderate induction of apoptosis. However, inhibition of XIAP alone was also not sufficient to enhance TRAIL-induced cell death. Synergistic increase in TRAIL-mediated killing of HL cells was only obtained by combination of
Rocaglamide and XIAP inhibitors. Our study demonstrates that targeting both c-FLIP and XIAP are necessary for an efficient treatment of HL.